Apply for financial support

To find the financial support program that may be right for you, answer a few questions with the financial assistance tool, which will guide you through the application process and any next steps.

Want more information about some of your options?
Take a look at some potential financial support programs.

Here are a few things you may need on hand:

  • Patient information: full name, date of birth, mailing address, email, phone (home and/or mobile) and insurance information
  • Prescribing doctor's information: first/last name, practice name, address and phone
  • Patient's financial eligibility information: number of people in the household (including patient) and annual net household income*

*not required for all programs

Contact Pulmozyme® Access Solutions

Need help? Contact Pulmozyme Access Solutions

Call 800-690-3023 (Mon.-Fri., 6AM-5PM PST)
Tips and Links

Tips & Helpful Links

Find information about nutrition, exercise and resources for people living with cystic fibrosis.

Downloadable Resources

Downloadable Resources from Pulmozyme

Get helpful documents and printable PDFs for people taking Pulmozyme.

Indication & Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.